Related Experiment Video
Updated: Apr 20, 2026

Fluorescence-mediated Tomography for the Detection and Quantification of Macrophage-related Murine Intestinal Inflammation
Published on: December 15, 2017
Molecular patterns in human ulcerative colitis and correlation with response to infliximab
Brendan Halloran1, Jessica Chang, David Q Shih
1*Division of Gastroenterology, Department of Medicine, University of Alberta, Edmonton, AB, Canada; †F. Widjaja Foundation, Inflammatory Bowel and Immunobiology Research Institute, Cedars-Sinai Medical Center, Los Angeles, California; ‡Alberta Transplant Applied Genomics Centre, Edmonton, AB, Canada; §Department of Laboratory Medicine and Pathology, University of Alberta, Edmonton, AB, Canada; and ‖Division of Nephrology and Transplant Immunology, Department of Medicine, University of Alberta, Edmonton, AB, Canada.
Ulcerative colitis (UC) molecular profiles resemble transplant rejection, showing gene expression changes that correlate with disease severity and predict infliximab treatment response. This molecular signature offers insights into therapeutic outcomes.
Area of Science:
- Gastroenterology
- Immunology
- Molecular Biology
Background:
- Ulcerative colitis (UC) is a T cell-mediated colonic disease.
- Molecular changes in T cell-mediated transplant rejection suggest shared pathogenic mechanisms.
- Investigating UC molecular profiles may reveal therapeutic response insights.
Purpose of the Study:
- To define the molecular phenotype of UC using microarrays.
- To compare UC molecular profiles with those of transplant rejection.
- To determine if molecular signatures predict infliximab response in UC.
Main Methods:
- Analyzed 56 colon biopsies from UC patients using microarrays.
- Correlated gene expression data with clinical and histological features.
- Examined 48 published microarray datasets of colon biopsies responding to infliximab.
Main Results:
- UC biopsies showed transcript changes similar to rejecting transplants.
- Gene expression disturbance (PC1) correlated with clinical and histological assessments.
- PC1 predicted infliximab response; intense disturbance indicated nonresponse.
Conclusions:
- The molecular phenotype of UC involves large-scale gene expression changes.
- These changes reflect inflammatory and parenchymal cell alterations.
- The molecular signature correlates with disease features and predicts infliximab response.
More Related Videos
09:44Evaluating Therapeutic Interventions in the SHIP-deficient Mouse Model of Crohn Disease-like Ileitis and Fibrosis
Published on: October 14, 2025
07:38Multimodal Quantitative Phase Imaging with Digital Holographic Microscopy Accurately Assesses Intestinal Inflammation and Epithelial Wound Healing
Published on: September 13, 2016
Related Concept Videos
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Inflammatory Bowel Disease II: Ulcerative Colitis
Inflammatory Bowel Disease IV: Clinical Manifestations
Drugs for Treatment of Ulcerative Colitis in IBD
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Inflammatory Bowel Disease I: Ulcerative Colitis
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...